The Filings Report

Madrigal Pharmaceuticals

MDGLNasdaqCIK 1157601Healthcare / Drug Manufacturersfiscal year ends December62 quarters since 2010

Revenue, Q2 FY2026
$364M
+71.2% on Q2 FY2025
Net income
−$58M
−37.0% on Q2 FY2025
Free cash flow
$19M
+140.5% on Q2 FY2025
Diluted EPS
$-1.99
−32.7% on Q2 FY2025
Revenue, TTM
$1.3B
trailing four quarters
Net margin, TTM
-25.3%
net income −$325M
Free cash flow, TTM
−$206M
−$198M less $9M capex
Cash and equivalents
$293M
long-term debt $341M, Jun 30, 2026
Shares, 12-month change
+3.7%
23M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$9.9B
at the close, buybacks

Latest quarter Q2 FY2026, filed July 30, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Madrigal Pharmaceuticals reported revenue of $364M, +71.2% on Q2 FY2025, and net loss of $58M (−37.0%). Operating margin was −15.5%. Free cash flow, operating cash flow less capital expenditures, was $19M ($23M less $4M). Diluted earnings per share were $-1.99.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of July 30, 2026.

Revenue and net incomeRevenueNet income
−$200M$0$200M$400MQ3'22, Revenue: $0Q3'22, Net income: −$81MQ3'22Q4'22, Revenue: $0Q4'22, Net income: −$86MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$77MQ1'23Q2'23, Revenue: $0Q2'23, Net income: −$86MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$99MQ3'23Q4'23, Revenue: $0Q4'23, Net income: −$112MQ4'23Q1'24, Revenue: $0Q1'24, Net income: −$148MQ1'24Q2'24, Revenue: $15MQ2'24, Net income: −$152MQ2'24Q3'24, Revenue: $62MQ3'24, Net income: −$107MQ3'24Q4'24, Revenue: $103MQ4'24, Net income: −$59MQ4'24Q1'25, Revenue: $137MQ1'25, Net income: −$73MQ1'25Q2'25, Revenue: $213MQ2'25, Net income: −$42MQ2'25Q3'25, Revenue: $287MQ3'25, Net income: −$114MQ3'25Q4'25, Revenue: $321MQ4'25, Net income: −$59MQ4'25Q1'26, Revenue: $311MQ1'26, Net income: −$94MQ1'26Q2'26, Revenue: $364MQ2'26, Net income: −$58MQ2'26−$200M$0$200M$400MQ3'22, Revenue: $0Q3'22, Net income: −$81MQ4'22, Revenue: $0Q4'22, Net income: −$86MQ4'22Q1'23, Revenue: $0Q1'23, Net income: −$77MQ2'23, Revenue: $0Q2'23, Net income: −$86MQ2'23Q3'23, Revenue: $0Q3'23, Net income: −$99MQ4'23, Revenue: $0Q4'23, Net income: −$112MQ4'23Q1'24, Revenue: $0Q1'24, Net income: −$148MQ2'24, Revenue: $15MQ2'24, Net income: −$152MQ2'24Q3'24, Revenue: $62MQ3'24, Net income: −$107MQ4'24, Revenue: $103MQ4'24, Net income: −$59MQ4'24Q1'25, Revenue: $137MQ1'25, Net income: −$73MQ2'25, Revenue: $213MQ2'25, Net income: −$42MQ2'25Q3'25, Revenue: $287MQ3'25, Net income: −$114MQ4'25, Revenue: $321MQ4'25, Net income: −$59MQ4'25Q1'26, Revenue: $311MQ1'26, Net income: −$94MQ2'26, Revenue: $364MQ2'26, Net income: −$58MQ2'26

Net income losses drawn in red.

Free cash flow
−$200M−$100M$0$100MQ3'22, Free cash flow: −$59MQ3'22Q4'22, Free cash flow: −$59MQ4'22Q1'23, Free cash flow: −$84MQ1'23Q2'23, Free cash flow: −$75MQ2'23Q3'23, Free cash flow: −$85MQ3'23Q4'23, Free cash flow: −$81MQ4'23Q1'24, Free cash flow: −$150MQ1'24Q2'24, Free cash flow: −$135MQ2'24Q3'24, Free cash flow: −$68MQ3'24Q4'24, Free cash flow: −$105MQ4'24Q1'25, Free cash flow: −$89MQ1'25Q2'25, Free cash flow: −$47MQ2'25Q3'25, Free cash flow: $79MQ3'25Q4'25, Free cash flow: −$133MQ4'25Q1'26, Free cash flow: −$171MQ1'26Q2'26, Free cash flow: $19MQ2'26−$200M−$100M$0$100MQ3'22, Free cash flow: −$59MQ4'22, Free cash flow: −$59MQ4'22Q1'23, Free cash flow: −$84MQ2'23, Free cash flow: −$75MQ2'23Q3'23, Free cash flow: −$85MQ4'23, Free cash flow: −$81MQ4'23Q1'24, Free cash flow: −$150MQ2'24, Free cash flow: −$135MQ2'24Q3'24, Free cash flow: −$68MQ4'24, Free cash flow: −$105MQ4'24Q1'25, Free cash flow: −$89MQ2'25, Free cash flow: −$47MQ2'25Q3'25, Free cash flow: $79MQ4'25, Free cash flow: −$133MQ4'25Q1'26, Free cash flow: −$171MQ2'26, Free cash flow: $19MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600M$800MQ3'22, Cash and equivalents: $59MQ3'22, Long-term debt: $49MQ3'22Q4'22, Cash and equivalents: $332MQ4'22, Long-term debt: $49MQ4'22Q1'23, Cash and equivalents: $113MQ1'23, Long-term debt: $84MQ1'23Q2'23, Cash and equivalents: $77MQ2'23, Long-term debt: $99MQ2'23Q3'23, Cash and equivalents: $62MQ3'23, Long-term debt: $115MQ3'23Q4'23, Cash and equivalents: $100MQ4'23, Long-term debt: $115MQ4'23Q1'24, Cash and equivalents: $623MQ1'24, Long-term debt: $116MQ1'24Q2'24, Cash and equivalents: $495MQ2'24, Long-term debt: $117MQ2'24Q3'24, Cash and equivalents: $233MQ3'24, Long-term debt: $117MQ3'24Q4'24, Cash and equivalents: $100MQ4'24, Long-term debt: $118MQ4'24Q1'25, Cash and equivalents: $184MQ1'25, Long-term debt: $118MQ1'25Q2'25, Cash and equivalents: $186MQ2'25, Long-term debt: $118MQ2'25Q3'25, Cash and equivalents: $296MQ3'25, Long-term debt: $340MQ3'25Q4'25, Cash and equivalents: $199MQ4'25, Long-term debt: $340MQ4'25Q1'26, Cash and equivalents: $227MQ1'26, Long-term debt: $340MQ1'26Q2'26, Cash and equivalents: $293MQ2'26, Long-term debt: $341MQ2'26$0$200M$400M$600M$800MQ3'22, Cash and equivalents: $59MQ3'22, Long-term debt: $49MQ4'22, Cash and equivalents: $332MQ4'22, Long-term debt: $49MQ4'22Q1'23, Cash and equivalents: $113MQ1'23, Long-term debt: $84MQ2'23, Cash and equivalents: $77MQ2'23, Long-term debt: $99MQ2'23Q3'23, Cash and equivalents: $62MQ3'23, Long-term debt: $115MQ4'23, Cash and equivalents: $100MQ4'23, Long-term debt: $115MQ4'23Q1'24, Cash and equivalents: $623MQ1'24, Long-term debt: $116MQ2'24, Cash and equivalents: $495MQ2'24, Long-term debt: $117MQ2'24Q3'24, Cash and equivalents: $233MQ3'24, Long-term debt: $117MQ4'24, Cash and equivalents: $100MQ4'24, Long-term debt: $118MQ4'24Q1'25, Cash and equivalents: $184MQ1'25, Long-term debt: $118MQ2'25, Cash and equivalents: $186MQ2'25, Long-term debt: $118MQ2'25Q3'25, Cash and equivalents: $296MQ3'25, Long-term debt: $340MQ4'25, Cash and equivalents: $199MQ4'25, Long-term debt: $340MQ4'25Q1'26, Cash and equivalents: $227MQ1'26, Long-term debt: $340MQ2'26, Cash and equivalents: $293MQ2'26, Long-term debt: $341MQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Madrigal Pharmaceuticals income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue36431132128721313710362+71.2%
Cost of revenue—————5———
Gross profit—————————
Research and development—————————
Selling, general and administrative289269240209197168141108+47.0%
Operating income(56)(93)(60)(114)(47)(79)(67)(116)−19.3%
Other income (expense)(1)(2)000000−1792.9%
Pretax income—————————
Income tax—————————
Net income(58)(94)(59)(114)(42)(73)(59)(107)−37.0%
Diluted EPS ($)(1.99)(3.25)—(4.01)(1.50)(2.61)—(4.92)−32.7%
Diluted shares (millions)2929—292828—22—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Madrigal Pharmaceuticals balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents293227199296186184100233+57.2%
Short-term investments546586785814611659826766−10.6%
Total current assets1,1991,1821,2461,3471,0039881,0331,064+19.5%
Total assets1,2451,2271,2601,3621,0159971,0421,073+22.6%
Total current liabilities374338310391197167169178+90.4%
Long-term debt341340340340118118118117+187.9%
Total liabilities721684657737319286288296+125.7%
Stockholders’ equity524543603626696711754777−24.7%
Shares outstanding (millions)2323232322222222—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed July 30, 2026.

Madrigal Pharmaceuticals cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 19, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Oct 31, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow23(167)(133)80(47)(89)(104)(67)+149.6%
Capital expenditures44010001—
Free cash flow (CFO − capex)19(171)(133)79(47)(89)(105)(68)+140.5%
Depreciation and amortization00000000+1.1%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed July 30, 2026.

Income statement

Madrigal Pharmaceuticals income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Mar 13, 2018FY2016ended Dec 31, 2016filed Mar 31, 2017FY2015ended Dec 31, 2015filed Mar 15, 2016FY2014ended Dec 31, 2014filed Mar 12, 2015FY2013ended Dec 31, 2013filed Mar 11, 2014FY2012ended Dec 31, 2012filed Mar 14, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011
Revenue95818000000——————0——
Cost of revenue—600————————————
Gross profit————————————————
Research and development————————————————
Selling, general and administrative81443510848372223158911616121211
Operating income(300)(498)(380)(294)(242)(207)(95)(41)(32)(25)(3)(84)(88)(61)(45)(37)
Other income (expense)000—————————————
Pretax income————————————————
Income tax00000000————————
Net income(288)(466)(374)(295)(242)(202)(84)(33)(31)(26)——————
Diluted EPS ($)(10.15)(17.31)(17.33)(17.23)(14.63)(13.09)————————(1.00)(0.93)
Diluted shares (millions)282722171715————————4740

Balance sheet

Madrigal Pharmaceuticals balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Mar 13, 2018FY2016ended Dec 31, 2016filed Mar 31, 2017FY2015ended Dec 31, 2015filed Mar 15, 2016FY2014ended Dec 31, 2014filed Mar 12, 2015FY2013ended Dec 31, 2013filed Mar 11, 2014FY2012ended Dec 31, 2012filed Mar 14, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011
Cash and equivalents19910010033236544757149190048823031
Short-term investments7858265342723423039242643———————
Total current assets1,2461,03363736127228544048519241099921014052
Total assets1,2601,042641363273287442485192410101951034254
Total current liabilities3101691191167747258105493132231517
Long-term debt340118115490———————————
Total liabilities6572882351657747258105493646282831
Stockholders’ equity60375440519719624041747718236(49)(42)49751523
Shares outstanding (millions)23222018171615151412138109856958—

Cash flow statement

Madrigal Pharmaceuticals cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 19, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Mar 13, 2018FY2016ended Dec 31, 2016filed Mar 31, 2017FY2015ended Dec 31, 2015filed Mar 15, 2016FY2014ended Dec 31, 2014filed Mar 12, 2015FY2013ended Dec 31, 2013filed Mar 11, 2014FY2012ended Dec 31, 2012filed Mar 14, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011
Operating cash flow(190)(456)(324)(225)(184)(158)(42)(26)(22)(18)——————
Capital expenditures0110000000001110
Free cash flow (CFO − capex)(190)(457)(326)(225)(184)(158)(42)(26)(22)(18)——————
Depreciation and amortization2110000000111112
Share repurchases—————————————0——
Dividends paid————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$7M
25 sales by 2 insiders; officers and directors $7M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$81M
202 sales by 9 insiders; officers and directors $81M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-160$533.09$32K202,907Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1106$534.06$57K202,801Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1218$535.94$117K202,583Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1160$537.62$86K202,423Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1687$540.59$371K201,736Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1368$541.64$199K201,368Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-11,202$542.60$652K200,166Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-11,539$544.02$837K198,627Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1761$544.83$415K197,866Sep 11, 2026
Sep 11, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1120$546.38$66K197,746Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1131$527.88$69K209,198Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1347$529.27$184K208,851Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1522$530.23$277K208,329Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1368$531.99$196K207,961Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1512$533.09$273K207,449Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1396$534.20$212K207,053Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1644$535.27$345K206,409Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-11,040$536.11$558K205,369Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1640$537.17$344K204,729Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1520$538.30$280K204,209Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1215$539.03$116K203,994Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1505$540.19$273K203,489Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1362$541.65$196K203,127Sep 11, 2026
Sep 9, 2026Sibold William JohnPresident and CEO, Directoropen-market sale10b5-1160$542.55$87K202,967Sep 11, 2026
Aug 17, 2026Kelley Shannon TGeneral Counselopen-market sale664$514.97$342K11,474Aug 20, 2026

Full insider history for Madrigal Pharmaceuticals, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held MDGL in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded MDGL by quarter.

FundManagerQuarterValueSharesWeightMove
Paulson & CoJohn PaulsonQ2 2026$720M1M27.94%trimmed −3.7%
Baron Capital GroupRon BaronQ2 2026$2M4,5000.00%trimmed −15.1%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
MADRIGAL PHARMACEUTICALS, INC., CIK 1157601 on EDGAR
Extract generated
August 27, 2026
Withheld
5 line-years whose four quarters do not sum to the filed year: depreciation amortization FY2011, depreciation amortization FY2012, depreciation amortization FY2013, depreciation amortization FY2014, depreciation amortization FY2015
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: operating income FY2015, opex sga FY2015
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: not filed
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/MDGL.json